Spot on Biotechnology Business 2017/2018 - D i - BIO.NRW
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
p a ny
Co m o r y
ct
D i re
Spot on Biotechnology Business 2017/2018
From Mind to Market:
Biotechnology Company Directory 2017/2018
North Rhine-Westphalia
BIO.NRW 4
BIO.NRW
Editorial
Dear Reader, The degree of efficiency is indicated by the
latest OECD statistics on biotech patents.
Biotechnology is one of the key technologies According to the survey, no other region in
of our century, and North Rhine-Westphalia Europe surpasses North Rhine-Westphalia
(NRW) is surely one of the main players when in terms of biotechnology related patents.
it comes to developing this technology. In an More precisely, if you look at the list of the
interstate comparison, NRW accounts for top ten applicants for European patents,
the highest turnover generated by biotech you cannot help noticing that, in the field of
companies (€1.64bn) in 2016, with a – quite biotechnology, three out of seven leading
remarkable - annual growth of 8.6 per cent. players are based in NRW.
North Rhine-Westphalia is home to one in The State Government strongly supports
five German biotech companies. biotechnology as one of North Rhine-West-
The biotechnology landscape in NRW phalia’s key industries. Conscious of the
extends from a strong academic sector great potential of the digital revolution, we
and highly renowned research institutes are therefore keen to create an innovation-
to dynamic start-ups as well as small and friendly environment with as little red tape
medium enterprises and global chemical as possible. This includes solid and efficient
and pharmaceutical players. This potent infrastructure to benefit our industries as a
mixture of different actors is one of North reliable economical partner in Germany, the
Rhine-Westphalia’s key strengths and forms European Union and throughout the world.
a network of local industrial sites which span
the entire state.
In the far west of NRW, the area surround-
ing Aachen and Jülich, top level engineering
institutions have established a close coop- This type of fundamental research is backed
eration with the biotech industry, paving the by a strong pharmaceutical industry, speed-
way for further advances in the life sciences. ing up the translation of academic findings
The Rhine-Ruhr region, on the other hand, to industrial innovation.
specialises in medical biotechnology: From The north-eastern corner of NRW is home Prof Dr Andreas Pinkwart
the southern tip, around Rheinbach near to those at the leading edge of nanotech-
Bonn down the river Rhine (Bonn, Cologne, nology, with a solid link to technological Minister of Economic Affairs, Innovation,
Düsseldorf, Wuppertal) and across to Dort- applications. There are also some highly Digitalization and Energy of the State of
mund at the eastern edge of the Ruhr, high- professional business incubators engaging North Rhine-Westphalia
end research institutions are busy working in the transfer of specialised technologies
on healthcare issues on a molecular level. right across the state.
5
BIO.NRW 6
BIO.NRW
Greeting
Dear Reader, 2016, we have been the local host of the
BIO-Europe, Europe’s biggest life science
the biotech landscape in North Rhine- partnering event, in Cologne, that set up
Westphalia (NRW) is in a constant process a new record in attendees and one-to one
of growth and development: within in the meetings. We wish this year’s venue and
last 10 years the total number of core bio- all attendees a successful networking, but
tech companies in NRW more than doubled first of all we would like to welcome you, for
from 53 in 2007 to 109 in 2016. In the same the 9 th time in a row, at the BIO.NRW booth.
time period numerous companies (e.g. I invite everybody to take advantage of our
Adhesys, evoxx, DIREVO Biotech AG etc.) offerings and to engage with our state’s
were subject of extensive merging & acqui- extensive and excellent biotech community,
sition activities of global players, further that we also proudly represent on our just
indicating the strength of NRW’s biotech recently completly remastered website.
economy. Based on top academic institu-
tions, numerous dynamics start-ups evolve
in an environment of successful small and
medium sized enterprises and world-wide
active global players. The excellence of
NRW biotechnological entrepreneurship is the successful development of the biotech
also confirmed by facts: NRW is Germany’s start-up scene in NRW. These activities
state with the highest turnover of biotech are supported by the region, e.g. through Dr. Bernward Garthoff
companies and in no other German state our quarterly held “BIO.NRW Business An- Cluster BIO.NRW
more employees are working in the biotech gels Zirkel” or “Business Angel Congress”,
industry. taking place annually. A more illustrated Representative for Biotechnology of the
Of course, this flourishing landscape did analysis of the key developmental facts German State of North Rhine-Westphalia
not just happen to emerge but instead has of this leading European biotech region is
been systematically generated within the provided in the 9th annual compendium of
last decade. During this time, several state- NRW’s biotech business landscape “Spot
of-the-art life science incubators were built on Biotech Business”.
across NRW and investors were attracted The NRW biotech community is strongly
to the life science hotspot “NRW”. Several connected locally but also internationally.
institutional investors, as for example the Collaborations around the world are a key
“High-Tech Gründerfonds”, Coparion, the strength. For example, a project on the
“NRW.BANK” and others, are headquar- internationalisation of clusters and net-
tered along the Rhine in Bonn, Cologne works supported by the federal ministry
and Dusseldorf. In addition, a NRW based of education in research (BMBF) was very
community of business angels specialized recently initiated by us together with our
in life sciences is focussing on young bio- partner country China, aiming to start new
tech companies and start-up projects. This B2B collaborations and intensify existing
variety of different investors in combination ones. Of course, we welcome any local and
with the corporate venture units of the international partners, who are seeking
global enterprises strongly contribute to international partnering opportunities.
7
BIO.NRW
© 2017/18, BIO.NRW “Spot on Biotechnology Business” www.bio.nrw.de
Print: Schloemer & Partner GmbH, Düren
Design and Layout: it’s FR!TZ
Picture Source:
p. 4 © Duesseldorf Marketing and Tourismus
p.5 © MWIDE NRW/Roberto Pfeil
p. 6 © Duesseldorf Marketing and Tourismus
p. 10 © tonaquatic - stock.adobe.com
p. 12 © Microgen - stock.adobe.com
p. 14 © Anatoly Fedotov - stock.adobe.com
p. 16 © Microgen - stock.adobe.com
p. 18 © YB - stock.adobe.com
p. 20 © tilialucida - stock.adobe.com
p. 22 © zinkevych - stock.adobe.com
p. 28 © tilialucida - stock.adobe.com
p. 37 © tilialucida - stock.adobe.com
p. 38 © luchschen - stock.adobe.com
p. 54 © BillionPhotos.com - stock.adobe.com
p. 60 © Swapan - stock.adobe.com
p. 64 © kentoh - stock.adobe.com
p. 66 © tilialucida - stock.adobe.com
8
BIO.NRW
Content
Editorial… ……………………………………………………………………………… 5 Company Directory 2017/2018 NRW
Greeting… ……………………………………………………………………………… 7 Non-specific Services… …………………………………………………… 28
Spot on Biotechnology Business… ………………………………… 11 Health and Medicine (including Animal Health)… …… 38
Biotech Landscape……………………………………………………………… 11 Industrial Biotechnology… ……………………………………………… 54
Stimuli for Start-Up‘s… ……………………………………………………… 11 Agrobiotechnology… ………………………………………………………… 60
Academic Biotech Research … ……………………………………… 13 Bioinformatics… ………………………………………………………………… 64
Biotech Business… …………………………………………………………… 15 Other Biotechnologically Active Companies……………… 66
Competence Clusters… …………………………………………………… 21 BIO.NRW Cluster Biotechnology
North Rhine-Westphalia… ……………………………………………… 72
Industrial Biotechnology – CLIB2021 ……………………………… 21
Pharmaceutical Biotechnology – BIO.NRW.red … …… 23 Glossary����������������������������� 74
From Mind to Market … …………………………………………………… 23 OECD Definition… ……………………………………………………………… 74
Organisation for Economic Co-operation and
Biotechnology Map of North Rhine-Westphalia Development (OECD)… …………………………………………………… 74
Life Science Technology Parks and Incubators�� 24
Biotechnology company… ……………………………………………… 74
Biotechnology Map of North Rhine-Westphalia Dedicated biotechnology companies … ……………………… 74
Dedicated and other biotechnologically active
companies ��������������������������� 26 Other biotechnologically active companies… …………… 74
Business Areas of Activity… …………………………………………… 74
Contact BIO.NRW……………………………………………………………… 74
Sources, Literature, Links… …………………………………………… 74
9
BIO.NRW 10
BIO.NRW
Spot on Biotechnology Business
Biotech Landscape and chemical industry. Today the state has pace for the powerful pulse of the state’s life
also developed into a life sciences hotspot: A science business. Meanwhile biotechnology
North Rhine-Westphalia (NRW) is at the heart good reason for many top-level biotechnology is a maturing industry that expands rapidly.
of Europe. 160 million people – almost a third companies and research institutes to have Its innovative technologies are applied to
of the population of the European Union – live their headquarters here. Numerous suc- major industry branches serving health/
within a day’s drive of Düsseldorf, the state cessful start-up and spin-off companies are medicine, chemistry, food and environment.
capital. 31.8 percent (i.e. EUR 180.9 billion in flourishing in NRW alongside a strong chemi- North Rhine-Westphalia has been developing
2015) of the direct foreign investment that cal and pharmaceutical industry that includes its biotechnology hotspot since 1995. More
flows into Germany ends up in North Rhine- many well-known household names like than 20 years into the program, over 450 life
Westphalia, where some 19.000 international Bayer, Evonik, Henkel, Grünenthal, Johnson science related companies are located here
companies control their German and Europe- & Johnson or UCB. This business excellence – among them 129 biotechnology enterprises
an operations from. NRW also is the number is endorsed by a dense network of outstand- including several global players (Figure 1).
one trading state among Germany’s 16 fed- ing academic institutions, which focus on Major business areas covered are industrial,
eral states.1 Summing up the in- and export biotechnology within a broad life sciences nano- and pharmaceutical biotechnology,
of NRW the trading volume is EUR 389 billion. landscape. In addition, there is an equally rich and there is a focus on enabling technologies
With around EUR 646 billion, NRW generates and robust funding environment to support and supporting services as well. Combining
21.7 % of the German GDP, putting it clearly and promote the industry, including venture the strong technical expertise evolving from
at the top of all German federal states. It ac- capital providers and business development these areas has been the key driver for NRW
counts for 4.5 percent of the European GDP organizations. as the state is pioneering the field of bio-
(EU-28), making it one of the most important Biotechnology in NRW represents an active, economy in Germany.
economic regions in Europe. Comparing NRW multi-centric network, which is setting the
in an international ranking, it is ahead of sev- Stimuli for Start-Up‘s
eral European countries such as Switzerland,
Sweden, Poland, and Belgium.1 With 17.7 mil- Many of today’s successful young biotech
lion inhabitants of which 8.1 million live in the 109 companies started as university spin-offs.
Rhine-Ruhr area, that lists among the top 20 dedicated They took advantage of life science incuba-
biotechnology
metropolitan areas in the world – NRW is by companies
tors and technology centers, whose existence
far the most populous German state. Conse- can be pivotal for a start-up company. As
quently, the state boasts the highest level of catalysts for regional infrastructure and eco-
20 other
infrastructure within Germany including the biotechnologically nomic development, there are approximately
country’s densest railway network and seven active companies 60 such centers and incubators in the im-
international airports. Handling more than mediate vicinity of universities and basic re-
133 million tons of goods per year, Duisburg is search institutions in NRW. Mostly 20% of all
the world’s largest inland port. With over 100 ~345 other life science German start-ups are based in NRW, the high-
related companies
annual international trade fairs NRW has the est rate of all German states2. They support
largest trade fair venue of the world. Colognes technology transfer all the way from mind to
“Koelnmesse” is the No.1 venue for more than market. At the time of the editorial deadline
25 different industries. Traditionally, North of this brochure, a total of 155 biotech and life
Rhine-Westphalia has been Germany’s most Fig. 1: Life Science Company Landscape in science related companies were incubated by
important location for the pharmaceutical North Rhine-Westphalia 25 of these technology centers.3 You will find
11BIO.NRW 12
BIO.NRW
the respective locations of the centers and Fig. 2: Biotechnology is a strongly linked industry
the number of biotech companies each of
them hosts on the map on page 24. The ser- IDEA MARKET
vices these start-up centers provide include
renting of affordable laboratory and office Branch Product/Service
space, mediating business contacts, consult-
ing on funding opportunities, and advising on
Energy Raw Materials/ Fuels
either founding or relocating a firm. Business-
Nanotechnology
plan competitions are offered as an additional (functionalized) Foods / Fertilizer / Crops /
chance for support. One technology park Agriculture
Plant Protection
that deserves to find special mention here is
BIOTECHNOLOGY
BioCampus Cologne, one of the largest of its Proteins / Peptides / Chemicals through Biotech
Chemical Industry
Processes (Enzymes, MO) / Molecular Electronics
type in Germany. It houses more than 23,000
square meters of office and laboratory space, Basic/fundamental / Pre-requisite for applied
Basic Research
including state of the art S1- and S2 labs, reserach and development
and industrial production facilities on a site Drug Delivery / (Companion) Diagnostics /
totaling more than 25 hectares. Company Healthcare / Pharma
Medical Devices / Therapeutics
Engineering
founders, young entrepreneurs and scien-
tists all profit from NRW’s highly-networked Facilities / Infrastructure Transport ⁄ Laboratory supply / Materials
biotechnology scene.
Laboratory Information Systems / Digital
(Biomedical) - IT
Academic Biotech Research Healthcare / Biological Computing / Databases
North Rhine-Westphalia is offering Ger-
many’s most comprehensive network of aca- Leibniz Institutes (11; 6 with life science activ- found in Aachen, Bonn, Cologne, Düsseldorf,
demic institutions consisting of internation- ity). One quarter of all German students are Münster, Bochum, Essen, Dortmund, Biele-
ally renowned Universities and Universities taking advantage of this excellent environ- feld, and other cities in the state. In the area
of Applied Sciences (71; 25 with life science ment for science and education and are pur- of biotechnology, specializations in cell biol-
activity), Max Planck Institutes (13; 6 with suing their studies in NRW, remarkably one ogy, (bio-) medicine, biochemistry, genom-
life science activity), Fraunhofer Institutes third of all STEM fields (Science, Technology, ics, proteomics, metabolomics, molecular
(14; 5 with life science activity), Helmholtz Engineering and Mathematics) students are biology, systems and synthetic biology,
Institutes (4; 4 with life science activity) and studying in NRW. University centers can be analytics/microsystems, bioinformatics and
Fig. 3: Key biotechnology facts; NRW and Germany
Annual turnover Total R&D expenditure (Mio. EUR)
Percentage of NRW
NRW * Germany **
relative to Germany 800
Number of
4,418 24,770 17.84
employees 600 750
Turnover Mio 1,765 3,634 48.57 3.6 bn EUR
400
R&D expenditure
368 1,118 32.92
Mio
200 368
Biotechnology
128 623 20.71
active companies
* data according to BioDeutschland survey - NRW, ** data according to Ernst & Young GmbH -
48.57 % 51.43 % 0
BioDeutschland survey - Germany NRW Rest of Germany NRW Rest of Germany
13BIO.NRW 14
BIO.NRW
Table 1: Temporal Development Key Figures for the Biotechnology Industry of North Rhine-Westphalia
109 dedicated biotechnology companies in 2016 (95 in 2015, 89 in 2014, 87 in 2013 )
2015 2016
2013 2014 2015 2016
(inputation) (inputation)
Number of
3,680 (n=67) 3,758 (n=68 ) 3,983 (n=75 ) 4229 4,044 (n=46) 4418
employees*
Turnover* EUR 1.27 bn (n=29) EUR 1.32 bn (n=25) EUR 1.51 bn (n=30) EUR 1.671 bn EUR 1.64 bn (n=28) EUR 1.765 bn
R&D
EUR 214 m (n=29) EUR 241 m (n=22) EUR 258 m (n=30) EUR 330 EUR 325 m (n=31) EUR 368 m
expenditure*
based on survey BIOCOM based on survey BioDeutschland
* Data based on survey data as indicated; n means number of companies giving indication
process engineering are all on offer. For over basic research to final therapeutics the CIO is Cologne and Bonn as well as their University
a decade, NRW has been the leading German currently being expanded for EUR 78 million. Hospitals plus the DZNE in Bonn, Cologne
region in stem cell research and development Here, newest research progress is directly has been developed into a world-wide unique
with Münster, Bonn and Cologne as hotspots. implemented into individual therapies for the competence center for ageing research. About
In the field of plant genetics, the Max-Planck- patient’s well-being. one hour west of Cologne, Europe’s most
Institute for Plant Breeding Research, Cologne innovative technology campus is currently
deserves to be called the “cradle of plant Fig. 4: Size of Dedicated Biotechnology taking shape: covering 800.000 square me-
biotechnology” in Germany as the first plant Companies (Number of Employees) ters, “Campus Melaten” of the RWTH Aachen
transformation technologies were developed 2,87% University will house up to 11 technology
here. It is now tightly interacting with the clusters, among them the “cluster biomedical
newly founded Cluster of Excellence on Plant technology” and take up investments of EUR 1
22,41%
Science (CEPLAS) that was founded in 2012 22,99% billion. Cooperation of academia and industry
– an EUR 32 million collaboration of several are creating synergy effects, e.g. the Forschun-
universities and research institutes. Recent gszentrum Jülich has a long-standing coop-
examples from Cologne emphasize the very eration with Siemens Medical Solutions to de-
24,14%
dynamic development of NRW as a research 27,59% velop specialized instruments and techniques
location: in May 2013 the all new research for brain research. BIO.NRW offers detailed
facilities of CECAD (Cluster of Excellence- information about the academic life science
Cellular Stress Responses in Aging-Associated landscape in NRW in its compendium “Spot
Diseases) have been opened – an investment on Biotechnology Science”. This brochure is
of EUR 85 million. In October 2013 the Max- below 10 10-49 50-99 composed in a similar manner like „Spot on
Planck Society opened the new facility of 100-249 more than 250 Biotechnology Business“ and presents a total
the Max-Planck Institute (MPI) for Biology of of 227 profiles of research institutes, centers
Ageing in immediate vicinity to the new CECAD Additionally several world leading neurosci- and facilities in NRW. Its second issue has been
building on the university campus. They offer ence institutes are located in close proximity. released in November 2016.
cutting edge infrastructure and technology, Alone in 2013 more than EUR 193 million was
incl. laboratory and office space for together invested into the neuroscience research facili- Biotech Business
more than 700 international scientists, staff ties of the DZNE (German Center for Neuro-
and students. Directly next to the MPI and degenerative Diseases) and the department Biotechnology became one of the most dy-
CECAD the Center for Integrated Oncology of the university hospital Bonn. Along with namic business sectors over the last decades.
(CIO) is located. To obtain a fast pipeline from the respective institutes of the Universities of Having such a complex industry it is hard to
15BIO.NRW 16
BIO.NRW
find a simple value chain or to separate it from Fig. 5: Areas of activity The real economic impact of biotechnology
other, more “static”, industries. Biotechnol- in NRW is therefore higher than these sta-
ogy routinely uses other technologies, e.g. 5% tistics reveal. These companies listed here
Nanotechnology and Engineering, to improve are at the innovative core of biotechnological
13% 25%
products. However, all colors of biotechnology research and development. In contrast to the
(green, red, white and blue) are linked to di- 4% business figures of the dedicated biotech
verse other branches like the chemical indus- companies – as an example – the 2016 sales
try (Figure 2). Looking on single services and 10% of Bayer AG and Evonik Industries AG alone,
24%
products makes it obvious, that looking only on 7% both headquartered in NRW, are EUR 46.8
dedicated biotechnology companies reveals a billion and EUR 12.7 billion, respectively. Even
minority of the impact biotechnology has on though only a part of their turnover can be
the entire industry. For example a recent report assigned to NRW sites and not all products
elucidated that the sum of the turnover of the Therapeutica Diagnostica are generated involving biotech processes, the
European bioeconomy industry, is more than Drug Delivery Non-specific services key business sectors of both companies are
EUR 2.1 trillion (!) and over 3.2 million people Bioinformatics Agrobiotechnology based on biotechnology. These two examples
are employed in bio-based industries, under- Industrial biotechnology clearly demonstrate the enormous impact
lying the importance of biotechnology on the
whole economy.4 Fig. 6: Drug Development Pipeline by Indication
Nevertheless, it is crucial to have uniform
definition of the core biotech companies to Indication Number of Products
monitor the development of the industry. This
is especially true for start-ups, as these are the Neoplasms / cancer / oncology 32
innovative center of the community. For this
purpose BIO Deutschland e.V., the branch as- Infectious and parasitic diseases 14
sociation of the German biotech industry and
organizations, annually carries out a statistical Diseases of the nervous system 10
analysis of the German core biotech compa-
nies, allowing a more sophisticated view of the Skin and subcutaneous tissue 5
biotechnology landscape in Germany. It was
carried out for the second time in 2017 will Symptoms, signs abnormal clinical and laboratory findings, not elsewhere classified 4
be continued in the next years, facilitating a
more comprehensive comparison for all indi- Musculoskeletal system and connective tissue 3
vidual German states over the next years. The
framework of the analysis is set by the OECD Diseases of the blood and blood-forming organs; immune disorders 2
definition of a dedicated biotech company
and biotech associated companies (see page Mental and behavioural disorders 2
74). Based on this definition, 109 dedicated
biotech companies were operating in NRW in Respiratory 2
2016. Their activities were complemented by
20 other companies with a biotechnological Endocrine, nutritional and metabolic diseases 1
commitment, mostly global players in the
field of pharmaceuticals, chemicals or seed Digestive system 1
production. Since these companies are active
in many diverse areas, their biotech related Other 1
business figures cannot be calculated exactly
and are not included in the following statistics. Total 76
17BIO.NRW 18
BIO.NRW
biotechnology has on the overall industry in position of NRW biotech. Together, NRW bio- GmbH (EUR 5 million), financing rounds of
NRW and Germany. tech firms are placing the highest investments biotech companies increased to EUR 19.8
According to the latest OECD Biotechno- for R&D of innovative products – nationwide. million in 2015, mostly contributed by PAION
logical Statistics report (which – except for Overall, the proportional expenditure, of AG with EUR 9.6 million. Of course, the to-
limited “indicator” updates – still is the latest biotech companies based in NRW, for R&D tal amount of non-public investments into
published detailed study in the field by the is with 20.9 % of the annual turnover more biotech companies in NRW was much higher
OECD), North Rhine-Westphalia is Europe’s than 7 times higher than the mean of all other than these numbers reveal. In addition to the
most innovative biotechnology region: It businesses in Germany (average of 2.87 %).9 big community of business angels based in
generates more biotech PCT patent applica- The numbers reflect that biotechnology as a NRW, numerous (institutional) investors set
tions than any other European region.5 The business sector is in the process of continu- up their business headquarter along the Rhine
development of biotech innovations from NRW ous maturation: 45.7 % of all new founded life within the last years. These investors strongly
has been constantly increasing: 4,121 biotech science companies are in fact biotech compa- foster young biotech companies. Investment
patents have been filed within 4 years by NRW nies (in 1996 17.6 % of all life science companies activities into life science companies are also
biotech companies and research facilities of were biotech companies, 27.4% in 2016). How- supported by the state, e.g. through our “BIO.
which 4,118 have been published.6 Of the top ever, important factors that reduce the average NRW Business Angel Zirkel” and our annually
ten patent applicants in Europe, seven are company age in the industry are new founda- “Business Angel Congress”.
biotechnology active companies and three of tions and acquisitions of successful ventures With fourteen new dedicated and one new
these, namely Bayer, Henkel and Evonik, are by global players as well as re-orientations other biotech-active companies in NRW in
based in NRW.7 of companies. The employee structure reflects 2016 the state’s biotech scene continues
The business figures of the 129 NRW bio- the mixture of companies based in NRW; to be one that’s growing at fastest pace in
technological actives companies are set into it is divided into four major fractions with Germany. Over the past two years the state
comparison with the 623 German biotech similar size and one small fraction; 22.4 % even counts 24 new companies leading to
companies. In NRW more than 4,418 people (of of all companies have less than 10 employees, 109 dedicated and 20 other biotech active
about 24,770 nationwide) – more than in any 46.6 % have less than 50 employees and 74.1 companies today (Table 2). The amount of
other German federal state – were employed % less than 100 employees. 23 % of all com- biotech companies in North Rhine-Westphalia
by dedicated biotech companies in 2016 and panies already reached a size of 100 – 250 that are active in multiple branches remained
generated a turnover of approximately EUR employees and 2.9 % employ more than 250 constant with 27 percent (Figure 5). These
1.64 billion (EUR 1.76 based on imputation people (Figure 4). biotechnology companies with “nonspecific
statistics) (Table 1). According to the national After financing rounds of EUR 17.7 million in business activities” include service providers
company survey by Ernest & Young – that is 2015, mostly due to Neuway Pharma GmbH and suppliers for the industry. Germany’s two
also based on BioDeutschland data – the NRW (EUR 5.9 million) and NEO New Oncology largest biotech companies with the highest
biotechnology active companies generated
about 48.6 % of the German biotech annual Fig. 7: Drug Development Pipeline by Phase
turnover (EUR 3.63 billion expected for whole
n/a Discovery
Germany based on imputation statistics) 13 8
(Figure 3).8 Thus, the biotech industry in On the Market Lead optimization
NRW is – to a large extend – responsible for 1 1
the economic impact of the German biotech Phase III
business as a whole. EUR 368 million – a sig- 1
nificant annual increase by 11.5 % compared Phase II
to 2015 (EUR 330 million) – was reinvested 3
Preclinical
into R&D projects. Phase I
40
The development of this key business 9
figures underlines that the investments by
the dedicated biotech companies in NRW are
persistent and will advance the future market
19BIO.NRW 20
BIO.NRW
numbers of employees in Germany7, QIAGEN Table 2: Number of dedicated biotech companies
GmbH and Miltenyi Biotec GmbH used to be
listed here. As Qiagen has developed into the NRW dedicated NRW biotech active Germany
Business Year**
field of medical applications, meanwhile the biotech companies companies / %* (active companies)
company is accounted as a dedicated biotech 2007 53 496
company in the „health-medicine“sector in 2008 61 501
this survey. QIAGEN began as a spin-off from
2009 68 531
the University of Düsseldorf in 1984. Today,
the company employs more than 4,700 ex- 2010 71 538
perts at 29 sites worldwide, and has become 2011 77 552
the leading provider of sample technology 2012 84 565
and a top player in molecular diagnostics
especially in cancer detection and prevention. 2013 87 570
Through a number of strategic moves QIA- 2014 89 579
GEN today is one of the leading companies 2015 95 114 / 19.3 590
in biomarker discovery and development (i.e.
2016 109 129 / 20.7 623
companion diagnostics), which is the basis
* % of Germany total , ** 2007 - 2014 based on survey by BIOCOM; 2015 - 2016 base on survey by BioDeutschland
for the company’s redirection to the health
business. Based on the invention of a mag-
netic cell separation technology, Miltenyi Bio- sue” (5) increased by 1 (4 products in 2016). characterize the biotechnology landscape in
tec was founded 1989 in Bergisch Gladbach The pipeline includes 13 therapeutics (13 North Rhine-Westphalia: Industrial Biotech-
near Cologne. Since then, the company has in 2016, Figure 7) in the clinical phases I to nology and Pharmaceutical Biotechnology.
expanded to 1,400 employees worldwide who III (17.1%).10 The majority of products (40 –
produce and market over 14,000 products for 52.6 %) are preclinical drug candidates. The Industrial Biotechnology – CLIB2021
the global biomedical research community. overall number of products in development
It is remarkable that this success has been pipeline slightly increased compared to 2016 CLIB2021 (Cluster Industrial Biotechnology
solely achieved by generic growth. The ma- with 72 products (+ 5.5 %). 2021) is an international open innovation
jority of dedicated NRW biotech companies With 14.8 percent (not accounting global cluster of large companies, SMEs, academic
(47 %; 46 % in 2016) are active in the field of key players) – compared to 10.2 percent of institutes and universities, as well as other
health and medicine developing new drugs companies in this sector across Germany stakeholders active in biotechnology and bio-
or diagnostics within the pharmaceutical – industrial biotechnology remains a char- economy as a whole. The cluster comprises
sector. At the time of the editorial deadline acteristic strength of NRW.11 The underlying over 100 members with a share of about 25
of this brochure the dedicated biotech com- classification refers to companies that de- % international members. The overall goal
panies in the field of health and medicine velop enzymes, biomaterials or bioprocesses, of CLIB2021 is to network stakeholders along
had developed a drug pipeline of in total 76 which can be applied to facilitate or enable and across value chains and to identify new
products and product candidates, remain- large-scale production in the chemical in- opportunities for innovation, projects, and
ing mostly constant over the last years. The dustry. The NRW-based companies Henkel business. Through this, the cluster develops
detailed distribution by indication lists as and Evonik have been pioneering indus- cross-sectoral biotechnological solutions
clear top one category “neoplasms/cancer/ trial biotechnology worldwide and are still for sustainable processes and products.
oncology”, with 31 products in pipeline in 2017 its pacesetters. Pertinent project areas are identified by the
(2016 - 32 products) (Figure 6). This is fol- CLIB2021 team in conjunction with members
lowed by “infectious and parasitic diseases” Competence Clusters in an iterative process. CLIB2021 is a non-profit
that increased from 10 (2016) to 14 products association, with its members shaping the
in pipeline (2017). “Diseases of the nervous Besides the large number of biotech com- cluster’s interests and activities. The cluster
system” (10) increased by 3 compared to panies, which have specialized in enabling coordinates several associated programmes
2016 with 7, and “skin and subcutaneous tis- technologies, two main fields of activity which cover different aspects of bioeconomy,
21BIO.NRW 22
BIO.NRW
and invites members to become involved, red biotechnology.12 And as well in NRW the By the end of 2014 a new series of competi-
bring in their own ideas and to generate a real key task of the most dedicated biotech com- tions were published by NRW’s state govern-
benefit for their companies or institutions. panies (42% out of 109) is developing drugs ment, focussing on translational research in
To this end, CLIB2021 organises a number of or diagnostics methods or find new ways for eight so-called “main markets” (NRW Leit-
events throughout the year: the annual CLIB drug delivery.10 marktwettbewerbe), adopting a “two-rounds
international conference (CIC), forum events, With a closer look to the overall German funding model”. Each round includes two calls
topic-specific workshops, dedicated small medical biotechnology area, respectively for proposals. The results of the two calls in
partnering meetings and visits to partners, to biopharmaceuticals, 14 out of 38 newly the first round in the main market “LifeS-
sites or meetings in Germany and abroad. approved drugs were biopharmaceuticals in ciences” is published on www.leitmarktagen-
In NRW, CLIB2021 is coordinating the regional 2016. 37% of the total is the highest percent- tur.nrw/leitmarktwettbewerbe/lifesciences.
innovation network (RIN) “Stoffströme”, which age since the first biopharmaceutical was ap- 19 innovative research projects are funded
seeks to improve the exploitation of biomass, proved. 12 And the sales of biopharmaceuticals by 38 Million euros.13 The start of the second
wastes, and side streams in the region. This in Germany also increased by 12.4 % in 2016 round will be expected in the last quarter of
action is funded by NRW’s Ministry of Culture relative to 2015 and reached a volume of about 2017. Members of the new successful consor-
and Science (MKW). Another NRW-based pro- EUR 9.3 billion, which corresponds to 24.8% of tia will expand the sustainable BIO.NRW.red
ject is dedicated to improve identification and the total pharmaceutical market in 2016. And network that connects major contributors
production of high performance ingredients the biopharmaceutical pipeline is still filled, to medicine, healthcare, the pharmaceutical
(HiPerIn) for markets like adhesives, cosmet- 636 compounds are in clinical development.12 industry and red biotechnology in the state.
ics, or food and feed. This action is funded by For more than a century, NRW has been
the Ministry of Economic Affairs, Innovation, the heartland of Germany’s pharmaceutical From Mind to Market
Digitalization and Energy of the State of North industry and has an exceptional standard
Rhine-Westphalia. Together with partners in biotechnological and medical education. This chapter provides an overview of 88 of
in Germany, Flanders, and the Netherlands, This advantage, combined with the enormous the dedicated and 12 of the other biotechno-
CLIB2021 is currently establishing the BioIn- market potential of biopharmaceuticals, gave logical-active companies from North Rhine-
novation Growth mega-Cluster (BIG-Cluster). reason for BIO.NRW’s strategic initiative in the Westphalia as classified following the OECD
This is supported by the German Federal field of red biotechnology called BIO.NRW.red. guidelines (page 74). For convenience, the
Ministry of Education and Research (BMBF) Its starting point was the competition “Bio. companies are grouped in five areas according
through a 5-year, 4 million Euro project, started NRW” in 2009, a call for projects announced to their main business:
in 2016. It develops cross-border novel value by NRW’s Ministry of Innovation, Science and
chains based on lignocellulose and the C1 Research (MIWF) to support the formation Non-specific Services
gases CO and CO2 to produce chemicals. It also of consortia between academia and biotech Health and Medicine
focuses on cross-border education concepts companies. The focal areas of the successful (including Animal Health)
conveying the required competences for the projects were: development of drugs (bio- Industrial Biotechnology
establishment of a circular economy. logicals and small molecules), generation of Agri/Agrobiotechnology
new methods in diagnostics, establishment of Bioinformatics
Pharmaceutical Biotechnology – biomarkers and introduction of new biophar- Other biotechnologically companies
BIO.NRW.red maceutical technology platforms – especially
based on cell cultures technology. For a more comprehensive directory that in-
In the last decades, major milestones in Since 2009 the MIWF announced several cludes all life science and life science related
medicine and healthcare have been achieved further calls for proposals in the field of red companies in NRW, please visit our company
through pharmaceutical (“red”) biotechnol- biotechnology like “PerMed.NRW” (by the database at www.bio.nrw.de/en/company_da-
ogy, namely in the development of drugs, end of 2010), focused on personalised medi- tabase.
vaccines and diagnostics. In 2016 we had cine and “Translational Stem Cell Research” BIO.NRW invites you to discover North
365 medical biotechnology companies in (finished in June 2014). These activities Rhine-Westphalia‘s biotechnology commu-
Germany. For many years most of the German continue to effectively boost the BIO.NRW. nity!
biotech companies are active in the field of red initiative.
23BIO.NRW
Biotechnology Map of North Rhine-Westphalia
Life Science Technology Parks and Incubators
The Netherlands
Q Gronau Weser
6
Q Bielefeld
1
6 Q Münster
Q Ascheberg Em Q Rheda-Wiedenbrueck
2 s
Rh
ine
Lippe
Q Bönen
Essen Dortmund 9
6 2 Q
1 Q Bochum
Q Q
2 27
Essen 4 2
3 Q Ruhr
Kempen
QQ Nettetal Witten Q Witten
1
Q Wuppertal
Düsseldorf Q
12 Q Hilden
Monheim
QQ
Langenfeld
10
3
Q Bergisch-Gladbach
7 3 Q24
BaesweilerQ 2 Köln
Herzogenrath 7 Q Jülich 2
Q
Q Troisdorf
Rh
2Q
in
9
e
Aachen Q
Bonn
Rheinbach Q 2
Belgium
Germany
24BIO.NRW
Name City Companies* Homepage
Zentrum für Bio-Medizintechnik (ZBMT) 9
1 Aachen www.agit.de
TZA -Technologiezentrum am Europaplatz Aachen 2
2 INCA Technologiezentrum GmbH Ascheberg 2 www.inca-technologiezentrum.de
3 its-Internationales Technologie- und Service-Center Baesweiler Baesweiler 7 www.its-center.de
Bergisch-
4 Technologiepark Bergisch-Gladbach 3 www.tbg.de
Gladbach
5 Technologiezentrum Bielefeld Bielefeld 1 www.technologiezentrum-bielefeld.de
6 BMZ - BioMedizinZentrum Bochum Bochum 6 www.bmz-bochum.de
7 TZR - Technologiezentrum Ruhr Bochum 2 www.chip-tzr.de
8 Bio-Security Bönen 9 www.bio-security.de
9 BMZ - BioMedizinZentrum Dortmund Dortmund 27 www.bmz-do.de
10 Zentrum für Mikro- und Nanotechnologie Dortmund 2 www.mst-factory.de
11 LSC - Life Science Center Düsseldorf Düsseldorf 12 www.lsc-dus.de
12 ETEC - Essener Technologie- und Entwicklungs-Centrum GmbH Essen 1 www.etec.de
13 TPH - Technologie Park Herzogenrath Herzogenrath 7 www.tph.de
14 Technologiezentrum Jülich Jülich 2 www.tz-juelich.de
15 TZN - Technologie- und Gründerzentrum Niederrhein GmbH Kempen 3 wwwtzniederrhein.de
16 BioCampus Cologne Grundbesitz GmbH & Co. KG Köln 24 www.biocampuscologne.de
17 RTZ - Rechtsrheinisches Technologie- und Gründerzentrum Köln Köln 3 www.rtz.de
18 TechnologiePark Köln Köln 2 www.tpk.de
19 Creative Campus Monheim Monheim 10 www.cc-monheim.de
www.technologiefoerderung-
20 Technologieförderung Münster GmbH Münster 6
muenster.de
21 CeNTech - Center for Nanotechnology Münster 6 www.centech.de
22 Gründer- und Technologiezentrum Rheinbach Rheinbach 2 www.wfeg-rheinbach.de
23 Forschungs- und Entwicklungs-Zentrum Witten GmbH Witten 4 www.fez.de
ZBZ - Zahnmedizinisch Biowissenschaftliches Forschungs- und
24 Witten 2 www.zbz-witten.de
Entwicklungszentrum Witten GmbH
25 Technologiezentrum Wuppertal W-tec GmbH Wuppertal 1 www.w-tec.de
Total: 25 155
* Life Science Companies
25BIO.NRW
Biotechnology Map of North Rhine-Westphalia
Dedicated and other biotechnologically active companies
Q
The Netherlands Osnabrück
Q Gronau Weser
Q Greven Q Bad Salzuflen
Münster
Q Bielefeld
Q Q Leopoldshöhe
Q Ascheberg Em
Q Rheda-Wiedenbrück
s
Bergkamen Q Bönen
Rh
ine
Q
Lippe
Q Bottrop
Q Marl
Gelsenkirchen Q Lippstadt
Q
Duisburg Q Q
Dortmund
Q Q
Moers Q Essen Bochum Q Witten
Ruhr
Q
Q Wuppertal
Nettetal
Düsseldorf Q Q Erkrath
Neuss Q MonheimQ Hilden
Mönchengladbach Q Q Q Langenfeld
Dormagen Q Q Leverkusen
Q Bergisch Gladbach
Baesweiler
Q Köln
Q Q Q Jülich
Herzogenrath Niederkassel Q Q Troisdorf
Q Würselen Q St. Augustin
Q Aachen
Q
Rh
ine
Bonn
Belgium
Germany
26BIO.NRW
Dedicated companies1, 3 Dr. Bartling GmbH Bielefeld
Morphoplant GmbH Bochum p. 48
A2M Pharma GmbH Monheim p. 39 multiBIND biotec GmbH Köln p. 58
Adhesys Medical GmbH Aachen p. 39 MykoMax GmbH Wuppertal p. 61
Affectis Pharmaceuticals AG Dortmund p. 39 Nanospot GmbH Münster
Agrojector UG Köln NEO New Oncology GmbH Köln p. 48
AgroProtect GmbH Aachen p. 61 NeraCare GmbH Bönen
AiCuris Anti-infective Cures GmbH Wuppertal p. 40 Neuway Pharma GmbH Bonn p. 49
Algiax Pharmaceuticals GmbH Erkrath p. 40 Nexigen GmbH Köln p. 49
aquila biolabs GmbH Baesweiler p. 29 NIPPON Genetics EUROPE GmbH Dueren
arrows biomedical Deutschland GmbH Münster p. 40 Orthogen AG Düsseldorf
ARTES Biotechnology GmbH Langenfeld p. 29 PAIA Biotech GmbH Köln p. 33
Autodisplay Biotech GmbH Düsseldorf p. 55 PAION AG Aachen p. 49
AxioGenesis AG Köln p. 41 PerkinElmer chemagen Technologie GmbH Baesweiler
AyoxxA Biosystems GmbH Köln p. 29 PharmedArtis GmbH Aachen p. 50
Baliopharm GmbH Jülich p. 41 Phytowelt Green Technologies GmbH Nettetal p. 62
BBT Biotech GmbH Baesweiler p. 30 PL BioScience GmbH Aachen p. 34
beniag GmbH Jülich p. 30 PlasmidFactory GmbH & Co. KG Bielefeld p. 34
Bibitec GmbH Bielefeld p. 30 Protagen AG Dortmund p. 50
BioCheck GmbH Münster p. 41 Protagen Protein Services GmbH Dortmund p. 34
BioEcho UG Dormagen p. 42 Protectimmun GmbH Bochum p. 50
Biofrontera AG Leverkusen p. 42 QIAGEN GmbH Hilden p. 51
Bio-Mar GbR Düsseldorf Qithera GmbH Düsseldorf p. 51
Bioreact GmbH Troisdorf QLAYM Healthcare AG Düsseldorf
BioSolveIT GmbH Sankt Augustin RheinCell Therapeutics GmbH Düsseldorf
bitop AG Witten p. 55 Ridom GmbH Münster p. 65
BSV Bioscience GmbH Baesweiler p. 55 Saaten-Union Biotec GmbH Leopoldshöhe p. 62
Carpegen GmbH Münster p. 42 SanguiBioTech GmbH Witten p. 51
CellAct Pharma GmbH Dortmund p. 43 SAW Instruments GmbH Bonn
CellSystems Biotechnologie Vertrieb GmbH Troisdorf p. 31 Scientific Biotech GmbH Köln
CEVEC Pharmaceuticals GmbH Köln p. 43 Senzyme GmbH Troisdorf p. 58
Charles River Biopharmaceutical Services GmbH Erkrath p. 31 SeSaM-Biotech GmbH Aachen p. 58
Chembiotech Münster SIT - Soft Intelligent Therapeutics GmbH & Co. KG Dortmund p. 52
Chimera Biotec GmbH Dortmund p. 31 Sividon Diagnostics GmbH Köln p. 52
CIBUS Biotech GmbH Rheda-Wiedenbrück p. 32 Soluventis GmbH Bochum p. 52
Cilian AG Münster p. 43 Squarix GmbH Marl p. 35
CIRES Cell & Immune Dortmund p. 44 Syntab Therapeutics GmbH Würselen p. 53
Colbourne Pharmaceuticals GmbH Niederkassel p. 44 Sysmex Partec GmbH Münster | Görlitz p. 36
Creative Therapeutics GmbH Wuppertal Taconic Biosciences GmbH Köln p. 35
Cube Biotech GmbH Monheim p. 32 Transimmune AG Düsseldorf p. 53
Cygenia GmbH Aachen p. 44 Vivo Science GmbH Gronau p. 35
Cysal GmbH Münster p. 56 W42 Industrial Biotechnology GmbH Dortmund p. 59
Deutsche Saatveredelung AG Lippstadt p. 61 XanTec bioanalytics GmbH Düsseldorf p. 36
DIREVO Industrial Biotechnology GmbH Köln p. 56 Xell AG Bielefeld p. 36
Dynavax GmbH Düsseldorf
evoxx technologies GmbH Monheim am Rhein p. 56 Other biotechnologically active companies2, 3
GEN-IAL GmbH Troisdorf p. 32
Genopath GbR Bonn BASF Personal Care and Nutrition GmbH Monheim
IIT Biotech GmbH Bielefeld p. 65 Bayer AG Leverkusen p. 67
IMAX Discovery GmbH Dortmund p. 57 Cellex Gesellschaft für Zellgewinnung mbH Köln
IMD Natural Solutions GmbH Dortmund p. 57 Evonik Degussa GmbH Essen
ImmunoQure AG Düsseldorf p. 45 Evonik Industries AG Essen p. 67
InfanDx AG Köln p. 45 German Seed Alliance GmbH Köln p. 67
Informium AG Bergisch Gladbach Grünenthal GmbH Aachen p. 68
Isoloid GmbH Düsseldorf Henkel AG & Co. KGaA Düsseldorf p. 68
Lead Discovery Center GmbH Dortmund p. 45 Janssen-Cilag GmbH Neuss p. 68
Life & Brain GmbH Bonn p. 46 Kyowa Hakko Europe GmbH Düsseldorf
Lonza Cologne GmbH Köln p. 33 Labopharm GmbH Bönen
m2p-labs GmbH Baesweiler p. 57 Monsanto Agrar Deutschland GmbH Düsseldorf p. 69
Mares Ltd. Greven p. 46 Octapharma GmbH Langenfeld
Matricel GmbH Herzogenrath p. 46 PHARMA WALDHOF GmbH Düsseldorf p. 69
Melema Pharma GmbH Köln p. 47 Succinity GmbH Düsseldorf
Metavi Labs GmbH Bottrop p. 47 Syngenta Seeds GmbH Bad Salzuflen p. 69
miacom diagnostics GmbH Düsseldorf p. 47 Taros Chemicals GmbH & Co. KG Dortmund p. 70
Miltenyi Biotec GmbH Bergisch Gladbach p. 33 UCB Pharma GmbH Monheim p. 70
MLM Medical Labs GmbH Mönchengladbach p. 48 W. von Borries-Eckendorf GmbH & Co.KG Leopoldshöhe p. 70
MolekularBiologisches & Biochemisches Labor WeissBioTech GmbH Aschberg
1 List of dedicated biotechnology companies in the fiscal year 2017 1 2 OECD Definition page 74
3 including company sites in NRW that are not headquarters and are therefore not accounted as
NRW-based companies in the annual study by “BIO Deutschland e.V.” 27Non-specific Services 28
BIO.NRW non-specific services
System) is the first easy-to-use and fully
Name aquila biolabs GmbH
automated solution for the feeding of liq-
uids into shake flasks.
aquila biolabs is a German company
providing innovative technologies for Address Arnold-Sommerfeld-Ring 2
shake flask and bioreactor fermentations. Postal Code/City 52499 Baesweiler
Currently, the company offers two main
products: CGQ and LIS. E-Mail info@aquila-biolabs.de
The Cell Growth Quantifier (CGQ) of- Internet www.aquila-biolabs.de
fers automated and non-invasive biomass
monitoring for various cultivations vessels Employees 10
such as shake flasks, serum bottles or Founded (year) 2014
glass bioreactors. LIS (Liquid Injection
recommendation, international registra-
Name ARTES
tion, EMA resp. FDA approval and GRAS Biotechnology GmbH
certification are achieved in international
collaborations. Expression platforms in- Address Elisabeth-Selbert-Str. 9
clude high yield yeasts and E. coli system Postal Code/City 40764 Langenfeld
ARTES Biotechnology is an independent for efficient protein production. Our unique
technology provider for the pharmaceuti- chimeric virus like particle (VLP) platform Fon+49 2173 27587-0
cal industry. Our business focus is on: METAVAX® is best suited for the develop- Fax+49 2173 27587-77
• vaccine development (VLP technology) ment of highly immunogenic vaccines in E-Mailinfo@artes-biotechnology.com
• process development of biopharma- human and animal health. Internetwww.artes-
ceuticals Our proprietary technologies ensure biotechnology.com
• transfer of biosimilar processes freedom-to-operate and reliable, competi- Employees 22
Our technologies have resulted in innova- tive production of innovative targets mar- Founded (year) 2002
tive products marketed worldwide. WHO keted worldwide.
sis of multiple biomarkers in picogram
Name AYOXXA Biosystems GmbH
amounts of biological samples, allowing
scientists to gain a maximum of high qual-
ity and reproducible insights. LUNARIS™ Address Nattermannallee 1
is fully scalable, with integrated, image- Postal Code/City 50829 Köln
based quality control and transparent data
AYOXXA Biosystems GmbH, based in processing and management, enabling Fon +49 221 222529-0
Cologne (Germany), is an international translational proteomics by addressing all Fax +49 221 222529-11
biotech company focused on the develop- the needs from basic to clinical research E-Mail info@ayoxxa.com
ment of its proprietary beads-on-a-chip and development. Internet www.ayoxxa.com
technology for advanced protein analysis. AYOXXA is commercializing and ex-
LUNARIS™. AYOXXA’s innovative multiplex panding a portfolio of detection kits cov- Employees 35
protein analysis platform is a fully integrat- ering ophthalmology, model-to-man and Founded (year) 2010
ed system designed for the parallel analy- immuno-oncology applications.
29non-specific services BIO.NRW
rators, filtration systems, chromatography
Name BBT Biotech GmbH
and freeze dryers. On the basis of individual
needs BBT Biotech GmbH also offers active
Address Arnold-Sommerfeld-Ring 28 pharmaceutical ingredients like thrombo-
Postal Code/City 52499 Baesweiler lytics (streptokinase, urokinase), fertility
hormones (HCG, HMG, FSH), inhibitors
Fon +49 2401 93310-0 BBT Biotech GmbH produces freeze-dried (Aprotinin, UTI) and others (Hyaluronidase,
Fax +49 2401 93310-90 viable bacteria (probiotics like lactobacilli, Corticotrophin).
E-Mail office@bbt-biotech.de bifidobacteria, yeasts) and metabolites not
Internet www.bbt-biotech.de only in bulk but also in finished dosage
forms to the pharmaceutical and health-
Employees 30 food industriy.
Founded (year) 1999 The fermenter capacity is up to 18.000 l.
The downstream process is based on sepa-
gate with extremely high efficiency within
Name beniag GmbH
a few minutes. The unique transfer mecha-
Address Huthmacherstrasse 20 nism allows manipulation of basically every
Postal Code/City 52428 Jülich mammalian cell type and incorporates
molecules directly into the cytosol, to guar-
Fon +49 2461 616734 antee their immediate bioactivity. beniag
+49 15780393499 beniag is a biotechnology company provid- focusses on production and development of
Fax +49 2461 613907 ing unique and highly efficient solutions to customer oriented solutions with coopera-
E-Mail info@beniag.com incorporate molecules into living cells and tion partners distributing the product line
Internet www.beniag.com tissue in vitro. Based on membrane fusion “Fuse-It” worldwide.
as a completely novel and patented trans-
Employees < 10 fer mechanism, beniag liposomes offer an
Founded (year) 2013 outstanding opportunity for customers to
incorporate any type of molecule or aggre-
The entire production and purification
Name BIBITEC GmbH
process was successfully transferred for
large-scale production leading to one of
the first successful approvals of a biosimi-
Address Universitätsstr. 25 BIBITEC Gesellschaft für Prozessentwick- lar in Europe.
Postal Code/City 33615 Bielefeld lung mbH is specialized in the production In 2012 BIBITEC became part of
and purification of proteins (e.g. hor- Nordmark Arzneimittel GmbH & Co. KG,
Fon +49 521 106-6326 mones, mAbs) derived from mammalian Uetersen. In cooperation with Nordmark
Fax +49 521 106-156233 cell cultures. and other validated partners BIBITEC pro-
Internet www.bibitec.de One major achievement was an eryth- vides all activities from “gene to product”
ropoietin (EPO) project that involved including cell line and process develop-
Employees 12 the process development and the GMP- ment, GMP production, fill-and-finish and
Founded (year) 2001 compliant production of an EPO biosimilar analytics.
for use in phase III clinical trials.
30You can also read
